[China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and schedules conference call for July 3, 2012 Fiscal Year 2012 Highlights: --Revenues reached record $94.4 million --Gross profit rose 30% to $27.6 million, gross margin 29% --Sales from the cultivation of Traditional Chinese Medicines were $4.2 million, from online drug sales was $1.1 million --Net income $8.1 million --Diluted]
[SCHEDULE 14A (Amendment No. 1) Check the appropriate box: [ ] Preliminary Proxy Statement CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of]
[SCHEDULE 14A (Amendment No. 1) Check the appropriate box: [ ] Preliminary Proxy Statement CHINA BIOLOGIC PRODUCTS, INC. __________________________________________________________ Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of]
[Amendment No.2 to FORM 20-F (Mark One) o OR x OR o OR o] [Framework Agreement on Repayment of Prepayment Among JingAo Solar Co., Ltd JA Solar Holdings Co., Ltd JA Solar Hong Kong Limited And M.Setek Co.,Ltd. Hebei Ningjin Songgong Semiconductor Co., Ltd Shanghai, China March 8, 2012 Agreement This Framework Agreement on Repayment of Prepayment (this JA Hebei JingAo Solar Co., Ltd ( JA Solar JA Solar Holdings Co., Ltd (] [I, Peng Fang, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; and 3. Based] [Certification by the Principal Financial Officer I, Min Cao, certify that: 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [(1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Peng Fang Chief Executive Officer EX-13.1 5 a12-15755_1ex13d1.htm EX-13.1] [Certification by the Principal Financial Officer (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Min Cao Chief Financial Officer EX-13.2 6 a12-15755_1ex13d2.htm EX-13.2]
[NEWS RELEASE CONTACT: Gary S. Maier Maier & Company, Inc. (310) 442-9852 HIGHWAY HOLDINGS REPORTS FISCAL FOURTH QUARTER/ YEAR-END RESULTS 2012 HONG KONG —June 29, 2012 — Nasdaq: HIHO Net income for the fiscal fourth quarter was $92,000, or $0.02 per diluted share, compared with $789,000, or $0.21 per diluted share, a year earlier. Net sales for the same period]
[NEWS RELEASE CONTACT: Gary S. Maier Maier & Company, Inc. (310) 442-9852 HIGHWAY HOLDINGS REPORTS FISCAL FOURTH QUARTER/ YEAR-END RESULTS 2012 HONG KONG —June 29, 2012 — Nasdaq: HIHO Net income for the fiscal fourth quarter was $92,000, or $0.02 per diluted share, compared with $789,000, or $0.21 per diluted share, a year earlier. Net sales for the same period]
[FORM 10-K þ For the fiscal year ended March 31, 2012 or o For the transition period from ____________________________________ to ________________________________________ 001-34711 CHINA JO-JO DRUGSTORES, INC . (Exact name of issuer as specified in its charter) Nevada 98-0557852 (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) Room 507-513, 5th Floor A Building, Meidu Plaza Gongshu District] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang Jiuxin Investment] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-171849) of China Jo-Jo Drugstores, Inc. and subsidiaries of our reports dated July 2, 2012 relating to the consolidated financial statements, which appear in this Form 10-K. New York, New York July 2, 2012 EX-23.1 3] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: 1. I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Chief Executive Officer July 2, 2012 EX-32.1 6 f10kex32i_chinajojo.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Ming Zhao Chief Financial Officer July 2, 2012 EX-32.2 7 f10kex32ii_chinajojo.htm CERTIFICATION]
[China Jo-Jo Drugstores, Inc. Reports Fiscal Year 2012 Earnings Results and schedules conference call for July 3, 2012 Fiscal Year 2012 Highlights: --Revenues reached record $94.4 million --Gross profit rose 30% to $27.6 million, gross margin 29% --Sales from the cultivation of Traditional Chinese Medicines were $4.2 million, from online drug sales was $1.1 million --Net income $8.1 million --Diluted]
